Log in

NASDAQ:ACIUAC Immune Stock Price, Forecast & News

$7.74
+0.11 (+1.44 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.56
Now: $7.74
$7.75
50-Day Range
$6.82
MA: $7.51
$7.90
52-Week Range
$4.07
Now: $7.74
$10.14
Volume120,100 shs
Average Volume84,952 shs
Market Capitalization$522.91 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
Read More
AC Immune logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACIU
CUSIPN/A
Phone41-21-345-9121

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.75 million
Cash Flow$0.66 per share
Book Value$4.06 per share

Profitability

Net Income$45.74 million

Miscellaneous

Employees92
Market Cap$522.91 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

How has AC Immune's stock been impacted by COVID-19 (Coronavirus)?

AC Immune's stock was trading at $5.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACIU shares have increased by 41.0% and is now trading at $7.74. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AC Immune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AC Immune.

When is AC Immune's next earnings date?

AC Immune is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for AC Immune.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) released its quarterly earnings results on Monday, March, 30th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.06. The business earned $1.07 million during the quarter, compared to analysts' expectations of $3.57 million. AC Immune had a negative return on equity of 8.71% and a negative net margin of 52.68%. View AC Immune's earnings history.

What price target have analysts set for ACIU?

1 Wall Street analysts have issued 1-year target prices for AC Immune's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate AC Immune's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 42.1% from the stock's current price. View analysts' price targets for AC Immune.

Has AC Immune been receiving favorable news coverage?

Media headlines about ACIU stock have been trending very positive on Tuesday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AC Immune earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAC Immune.

Who are some of AC Immune's key competitors?

What other stocks do shareholders of AC Immune own?

Who are AC Immune's key executives?

AC Immune's management team includes the following people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 61)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 41)
  • Mr. Piergiorgio Donati, Head of Technical Operations & Program Management (Age 48)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 61)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 48)

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Prosight Management LP (1.57%), Acadian Asset Management LLC (1.11%), BlackRock Inc. (0.87%), Wells Fargo & Company MN (0.31%), Private Advisors LLC (0.11%) and Athanor Capital LP (0.11%).

Which institutional investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, BlackRock Inc., Athanor Capital LP, GSA Capital Partners LLP, Morgan Stanley, and State Street Corp.

Which institutional investors are buying AC Immune stock?

ACIU stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Private Advisors LLC, AJO LP, Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Squarepoint Ops LLC, Engineers Gate Manager LP, Two Sigma Advisers LP, and Mackenzie Financial Corp.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $7.74.

How big of a company is AC Immune?

AC Immune has a market capitalization of $522.91 million and generates $111.75 million in revenue each year. The company earns $45.74 million in net income (profit) each year or $0.60 on an earnings per share basis. AC Immune employs 92 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is www.acimmune.com.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.